-+ 0.00%
-+ 0.00%
-+ 0.00%

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Barchart·12/31/2025 07:00:00
Listen to the news


TARPON SPRINGS, Fla., 
December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.

Dear Shareholders,

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.